Contactin-1 autoimmunity
Serologic, neurologic, and pathologic correlates

Divyanshu Dubey, MD, Josephe A. Honorat, MD,* Shahar Shelly, MD,* Christopher J. Klein, MD, Lars Komorowski, MD, PhD, John R. Mills, PhD, Stefanie Brakopp, PhD, Christian Probst, PhD, Vanda A. Lennon, MD PhD, Sean J. Pittock, MD, and Andrew McKeon, MD

Neurol Neuroimmunol Neuroinflamm 2020;7:e771. doi:10.1212/NXI.0000000000000771

Abstract

Objective
To determine serologic characteristics, frequency, phenotype, paraneoplastic associations, and electrodiagnostic and histopathologic features accompanying contactin-1 autoimmunity.

Methods
Archived sera known to produce synaptic tissue-based immunofluorescence patterns were reevaluated, and contactin-1 specificity was confirmed by recombinant protein assays. Screening of 233 chronic/relapsing demyelinating neuropathies for additional cases was performed.

Results
We identified 10 contactin-1 IgG seropositive cases. Frequency of contactin-1 immunoglobulin (Ig) G among tested Mayo Clinic chronic/relapsing demyelinating neuropathies was 2%. Sensory predominant presentations (n = 9, 90%), neuropathic pain (n = 6, 60%), and subacute progression (n = 5, 50%) were commonly encountered among contactin-1 neuropathies. Two patients had chronic immune sensory polyradiculopathy-like phenotype at presentation. Electrodiagnostic studies were consistent with demyelination (slowed conduction velocities and/or prolonged distal latencies) without conduction block. Markedly elevated CSF protein (median 222 mg/dL, range 69–960 mg/dL), thickening/gadolinium enhancement of nerve roots (4/5), and subperineural edema on nerve biopsy (4/4) were other characteristic features. Three cases were diagnosed with paraneoplastic demyelinating neuropathies (thymoma, n = 1; breast cancer, n = 1; plasmacytoma, n = 1). Four of the 9 patients treated with IV immunoglobulin demonstrated initial clinical improvement, but the favorable response was sustained in only 1 case (median follow-up, 60 months). Sustained clinical stabilization or improvement was observed among 3 of the 6 cases in whom second-line therapies (rituximab, cyclophosphamide, and azathioprine) were used.

Conclusion
Contactin-1 IgG has a distinct sensory predominant presentation commonly associated with neuropathic pain, with demyelinating changes on electrophysiologic studies. A paraneoplastic cause should be considered. Testing of contactin-1 IgG among cases with similar presentations may guide immunotherapy selection, especially second-line immunotherapy consideration.

*Contributed equally.


Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
A minority of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) cases have been demonstrated to have antibodies targeting paranodal antigens such as neurofascin-155 and contactin-1.1-5 Herein, we provide a retrospective clinical review of 10 contactin-1 neuropathy cases identified: (1) in the course of evaluation of consecutively acquired specimens in the Neuroimmunology Laboratory, Mayo Clinic, and (2) by screening sera from a CIDP cohort.

Methods

Standard protocol approvals, registrations, and patient consents
The Mayo Clinic Institutional Review Board (#08–006647) approved human specimen acquisition and chart retrospective review.

Study population and laboratory methods
As previously described,6 between January 1, 1993, and June 1, 2019, the Mayo Clinic Neuroimmunology Laboratory tested 616,025 serum and CSF specimens submitted for service testing for autoimmune neurologic disorders by tissue-based indirect immunofluorescence assay (IFA). Of those, 368 samples (serum, n = 334; CSF, n = 34) produced diffuse neural-restricted synaptic staining by IFA. From that specimen cohort, sera from 4 patients with available medical records produced an identical unique staining pattern (supplementary figure 1A, links.lww.com/NXI/A261). Contactin-1 was determined to be the autoantigen (previously described3) by immunoprecipitation and mass spectrometry (supplementary methods, links.lww.com/NXI/A262). Antigen specificity was confirmed by Western blot, cell-based assays (transfected HEK293 cells; Euroimmun [supplementary figure 1B, links.lww.com/NXI/A261]), and confocal microscopy.

An additional 5 patients were identified among 233 stored specimens from patients diagnosed with chronic/relapsing demyelinating neuropathy were tested (CIDP, n = 225 [sera, n = 210; CSF, n = 15]; chronic immune sensory polyradiculopathy [CISP], n = 8). Another contactin-1 immunoglobulin (Ig) G-seropositive case (Western blot, Washington University Laboratory) with insufficient sample for cell-based assay testing was included.

We also evaluated stored sera from 39 patients with monophasic acute inflammatory demyelinating polyradiculoneuropathy (AIDP, n = 25) or polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS, n = 14). Clinical outcome was assessed by the Inflammatory Neuropathy Cause and Treatment disability score.7

Data availability
All methods are available above, and data are published in this article.

Results

Demographic and clinical findings
Five of the 10 contactin-1 IgG-seropositive cases were men, and the median symptom onset age was 61 years (range, 19–82 years). The frequency of contactin-1 seropositivity among Mayo Clinic acquired demyelinating neuropathy cohort was 2% (5/233).

All 10 had inflammatory demyelinating neuropathy diagnosis. Symptomatic onset to nadir was <8 weeks in 5 of the 10 patients, leading to their initial diagnosis of AIDP (n = 4) or subacute inflammatory demyelinating polyradiculoneuropathy (n = 1).8 Two of the 10 cases were diagnosed of CISP-like phenotype at initial presentation (table).

Paraproteinemic and oncologic associations
Four of the 10 cases had monoclonal gammopathies (IgM, n = 2; IgG, n = 2) detected by serum protein electrophoresis. Bone marrow biopsy in 1 patient demonstrated clonal proliferation consistent with plasmacytoma. A mediastinal lymph node in another patient led to a diagnosis of Rosai-Dorfman disease. In addition, solid tumors were detected in 2 of the 9 patients within 6 months onset of neuropathy symptoms (breast cancer, n = 1; thymoma, n = 1).

Sensory predominant presentations
Nine patients reported initial sensory symptoms (numbness and paresthesia) preceding the onset of weakness. Weakness was noticed a few days later by 7 of those 9 patients (median interval 14 days; range 1–4 weeks). However, 2 patients lacked objective evidence of weakness on neurologic examination; a diagnosis of CISP (figure 1, A and B) was suspected.9 Weakness in 3 cases started in the arms (asymmetric) and spread to a lower extremity. Three patients additionally reported cranial nerve palsies at initial presentation (cranial nerve [CN] VII, n = 1; CN III and XII, n = 1; CN V, n = 1). Nine patients had sensory ataxia with...
Neurology.org/NN

Neurology: Neuroimmunology & Neuroinflammation | Volume 7, Number 4 | July 2020

Closely approximated osmium-fixed teased nerve fibers in 1 case’s fascicular root biopsy demonstrated widened nodes of Ranvier with demyelination (figure 2A); sural nerve biopsy from 2 patients (figure 2, C–E) demonstrated axonal degeneration, including empty nerve strands (decreased density of myelinated fibers). Semithin preparations of fascicular root and both sural nerve biopsies showed subperineurial edema (figure 2, D–F) without onion bulb formation or significant epineurial or endoneurial inflammatory infiltrates. One patient with enlarged proximal nerves on MRI underwent femoral nerve segment resection, but biopsy only revealed significant subperineurial and endoneurial edema without evidence of nerve sheath neoplasm.

**Immunotherapy and clinical outcomes**

All except 1 patient (9/10) was treated with intravenous immunoglobulin (IVIG). Other first-line therapies included plasmapheresis (4/9) and IV corticosteroids (2/9). Four of the 9 patients who received IVIG as first-line immunotherapy improved, but 3 of those 4 relapsed within 4 weeks and became refractory to retreatment with IVIG. Among 3 patients with undetectable subtype anti-contactin IgG4 in our series, 2 received IVIG and 1 received plasmapheresis as first-line immunotherapy. None of these 3 cases had a sustained response to first-line therapy and had a relapsing or progressive course.

Six of the 10 contactin-1 neuropathy cases received second-line immunosuppressive agents (rituximab, n = 2; mycophenolate mofetil, n = 2; cyclophosphamide, n = 1; azathioprine, n = 1). Two of those patients stabilized (cyclophosphamide and azathioprine) and 1 (infused with rituximab) improved. Five patients were using a wheelchair for ambulation at last follow-up. The median follow-up period was 60 months (range, 4–180 months).

**Discussion**

This study demonstrates a 2% frequency of contactin-1 IgG seropositivity in a US-based tertiary care cohort of patients with diverse immune-mediated demyelinating neuropathies, similar to the frequency reported in a Japanese population (2%). In addition, our systematic screening of specimens referred for diverse clinical indications confirms that contactin-1 IgG is highly specific for demyelinating neuropathy.

**Table** Clinical, CSF, electrodiagnostic, and MRI characteristics of contactin-1 neuropathies

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Contactin-1 neuropathies (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age at onset, y (range)</td>
<td>61 (19–82)</td>
</tr>
<tr>
<td>Female (%)</td>
<td>5 (50)</td>
</tr>
<tr>
<td>Acute/subacute progression to nadir (%)</td>
<td>5 (50)</td>
</tr>
<tr>
<td>Sensory symptoms preceding weakness (%)</td>
<td>9 (90)</td>
</tr>
<tr>
<td>Cranial neuropathy at presentation (%)</td>
<td>3 (30)</td>
</tr>
<tr>
<td>Neuropathic pain at onset (%)</td>
<td>6 (60)</td>
</tr>
<tr>
<td>Sensory ataxia on examination (%)</td>
<td>9 (90)</td>
</tr>
<tr>
<td>Pseudoathetosis (%)</td>
<td>2 (20)</td>
</tr>
<tr>
<td>Weakness on examination (%)</td>
<td>8 (80)</td>
</tr>
<tr>
<td>Onset of weakness in upper extremities (%)</td>
<td>3 (30)</td>
</tr>
<tr>
<td>Tremors (%)</td>
<td>1 (10)</td>
</tr>
<tr>
<td>Dysarthria (%)</td>
<td>0</td>
</tr>
<tr>
<td>Malignancies identified (%)</td>
<td>3 (30)</td>
</tr>
<tr>
<td>Monoclonal gammopathies (%)</td>
<td>4 (40)</td>
</tr>
<tr>
<td>Median CSF protein (range)</td>
<td>222 (69–960)</td>
</tr>
<tr>
<td>Nerve root thickening and enhancement on initial MRI (%)</td>
<td>4/5 (80)</td>
</tr>
<tr>
<td>Demyelinating features on NCS or SSEP (%)</td>
<td>10 (80)*</td>
</tr>
<tr>
<td>Conduction block (%)</td>
<td>0</td>
</tr>
<tr>
<td>Subperineurial edema on nerve biopsy (%)</td>
<td>4/4 (100)*</td>
</tr>
<tr>
<td>Wheelchair dependent at last follow-up (%)</td>
<td>5 (50)</td>
</tr>
</tbody>
</table>

Abbreviations: NCS = nerve conduction study; SSEP = somatosensory evoked potential. *Two patients with chronic immune sensory polyradiculopathy-like presentation had normal initial NCS, but SSEPs consistent with demyelinating sensory polyradiculopathies.
Most of the seropositive patients we identified had a distinctive sensory predominant presentation, some with neuropathic pain. Prolonged SSEPs (figure 1, A and B) consistent with the patient’s sensory ataxia localized to sensory roots. However, involvement of dorsal root ganglia as previously reported cannot be excluded. One-third of our cases had cranial nerve involvement, and half of the cases had aggressive disease progression. Oncologic associations in 3 cases included thymoma, breast cancer, and plasmacytoma. One was diagnosed with Rosai-Dorfman disease. Previous descriptions of patients with contactin-1 neuropathy have demonstrated electrophysiologic characteristics mimicking seronegative CIDP. However, our electrophysiologic studies demonstrated only slowing of conduction velocity and no conduction blocks. Electrophysiologic features we encountered have been typically associated with POEMS syndrome rather than CIDP.

The nerve biopsy finding of subperineural edema is supportive of altered blood-nerve barrier and suggests polyradicular localization. Consistent with a previously reported sural nerve biopsy from a single case of autoimmune contactin-1 neuropathy, the teased preparation of a fascicular root biopsy of one of our patients revealed segmental demyelination (figure 2A) and absence of onion bulbs.

The majority of cases either failed to improve following IVIG therapy or soon relapsed after initial transient improvement, but 1 patient had sustained clinical improvement (figure 1, A and B). The long-term wheelchair dependence of 5 of our 10 cases underscores the higher morbidity associated with autoimmune contactin-1 neuropathy compared with idiopathic CIDP. Retrospective design and small number of seropositive cases limit our assessment of optimal chronic immunotherapy selection. However, the described phenotypic, electrodiagnostic, and histopathologic features we describe may guide clinicians in considering serologic evaluation for contactin-1 IgG in patients with demyelinating neuropathy.

**Study funding**

This work was funded by the Center for Individualized Medicine and Euroimmun AG. The Center for Individualized Medicine and Euroimmun AG provided Neuroimmunology fellowship grant for Josephe A. Honorat.

**Disclosure**

D. Dubey has a patent pending for Kelch-like protein 11 as a marker of neurological autoimmunity and has received research support from Grifols, Center of Multiple Sclerosis and Autoimmune Neurology, and Center for Clinical and Translational Science. D. Dubey has consulted for UCB and...
Figure 2  Nerve pathology of contactin-1 IgG neuropathy is distinct from classic-CIDP

Astellas. All compensation for consulting activities is paid directly to Mayo Clinic. J.A. Honorat has a patent pending for septin-5-IgG as biomarker of autoimmune neurological disease. S. Shelly reports no disclosures. C.J. Klein reports honorarium from Akcea for teaching on TTR amyloid and Fabry disease and is a consultant for Pfizer Pharmaceuticals on TTR amyloidosis. L. Komorowski is employed by Euroimmun AG. J.R. Mills reports no disclosures. S. Bra-kopp and C. Probst are employed by Euroimmun AG. V.A. Lennon has a patent application pending for septin-5 IgG as a biomarker of autoimmune neurologic disease. She has a financial interest in the following intellectual property: “Marker for Neuromyelitis Optica.” A patent has been issued for this technology, and it has been licensed to commercial entities. They have received cumulative royalties of greater than the federal threshold for significant financial interest from the licensing of these technologies, but receive no royalties from the sale of these tests by Mayo Medical Laboratories. S.A. Pittock receives personal fees and non-financial support from Alexion Pharmaceuticals and MedImmune, Inc. He receives grant/research support from Alexion, Grifols, MedImmune, and Autoimmune Encephalitis Alliance. He received personal compensation for attending the UCB Advisory Board Meeting in Stockholm, Sweden, on September 10, 2019. He is a named inventor on filed patents that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker and has a patent pending for MAP1B, Septin 5, Kelch-like protein 11, and GFAP as markers of neurological autoimmunity and paraneoplastic disorders. All compensation for consulting activities is paid directly to Mayo Clinic. A. McKeon has patent pendings for MAP1B, Kelch-like protein 11, PDE10A, GFAP, and Septins 5 and 7 as markers of neurological autoimmunity and paraneoplastic disorders; has consulted for Grifols, MedImmune, Inc, and Euroimmun; and has received research support from MedImmune, Inc and Euroimmun but has not received personal compensation. Go to Neurology.org/NN for full disclosures.

Publication history
Received by Neurology: Neuroimmunology & Neuroinflammation February 14, 2020. Accepted in final form April 21, 2020.
Appendix Authors

- Divyanshu Dubey, MD: Designed and conceptualized the study; analyzed the data; and drafted the manuscript.
- Josephe A. Honorat, MD: Acquired data; interpreted the data; and revised the manuscript for intellectual content.
- Shahar Shelly, MD: Acquired data; interpreted the data; and revised the manuscript for intellectual content.
- Christopher J. Klein, MD: Interpreted the data and revised the manuscript for intellectual content.
- Lars Komorowski, MD, PhD: Interpreted the data and revised the manuscript for intellectual content.
- John R. Mills, PhD: Interpreted the data and revised the manuscript for intellectual content.
- Stefanie Brakopp, PhD: Interpreted the data and revised the manuscript for intellectual content.
- Christian Probst, PhD: Interpreted the data and revised the manuscript for intellectual content.
- Vanda A. Lennon, MD, PhD: Interpreted the data and revised the manuscript for intellectual content.
- Sean J. Pittock, MD: Interpreted the data and revised the manuscript for intellectual content.
- Andrew McKeon, MD: Design and conceptualized the study; analyzed the data; revised the manuscript for intellectual content; and provided study supervision.

References

Contactin-1 autoimmunity: Serologic, neurologic, and pathologic correlates
Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000771

This information is current as of May 27, 2020